Key clinical point: Elotuzumab may have synergistic clinical activity with pomalidomide against multiple myeloma.
Major finding: Median progression-free survival was 10.3 months with elotuzumab, pomalidomide, and dexamethasone vs. 4.7 months with pomalidomide and dexamethasone.
Study details: Randomized open-label phase 2 trial of 120 patients with multiple myeloma relapsed or refractory after 2 or more prior lines of therapy.
Disclosures: Bristol-Myers Squibb and AbbVie Biotherapeutics funded the study. Dr. Dimopoulos disclosed honoraria and/or consulting fees from Amgen, BMS, Celgene, Janssen and Takeda.
Source: Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.
Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.
This Week's Must Reads
Must Reads in Multiple Myeloma
Study supports long-term survival in multiple myeloma subgroup, Usmani SZ et al. Blood Cancer J. 2018 Nov 23;8(12):123
Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.
Osteoporosis tied to mortality risk in women with multiple myeloma, Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.
Simulated model could target myeloma treatment, Ubels J et al. Nat Commun. 2018 Jul 27. doi: 10.1038/s41467-018-05348-5.
Researchers propose frailty index for older patients with multiple myeloma, Mian HS et al. JCO Clin Cancer Inform. 2018 Jul 25. doi: 10.1200/CCI.18.00043.